Natco Pharma is considering acquisitions in Rest of the World (RoW) markets to strengthen its core business. “The acquisition space is intended to bolster our primary operations. We have the financial capacity to pursue this and are focusing on RoW markets. Although we haven’t finalized any deals yet, we are hopeful for progress in the next couple of years,” stated Rajeev Nannapaneni, Director and CEO of Natco Pharma.
Hyderabad-based Natco has been working on expanding its reach, recently investing around $2 million in Cellogen Therapeutics Private Ltd, a Delhi-based biotech start-up. Given Natco’s strong presence in oncology, this move could benefit their business in the long run.
Regarding the agricultural sector, Nannapaneni noted that the company’s target for FY24 was between ₹140 – ₹150 crore, but they fell short by about ₹25 crore due to poor monsoon conditions and some returns. “Overall, it’s a promising business. We have built a strong brand in a short time and can provide more specific guidance on business performance around the June quarter,” he added. As reported by businessline, Natco remains optimistic about launching several first-time generics in the agro business in the future.
